Quantifying the primary and secondary effects of antimicrobial resistance on surgery patients: Methods and data sources for empirical estimation in England.
antimicrobial resistance
burden
secondary effects
surgery
surgical site infection
Journal
Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
10
2021
accepted:
04
07
2022
entrez:
29
8
2022
pubmed:
30
8
2022
medline:
31
8
2022
Statut:
epublish
Résumé
Antimicrobial resistance (AMR) may negatively impact surgery patients through reducing the efficacy of treatment of surgical site infections, also known as the "primary effects" of AMR. Previous estimates of the burden of AMR have largely ignored the potential "secondary effects," such as changes in surgical care pathways due to AMR, such as different infection prevention procedures or reduced access to surgical procedures altogether, with literature providing limited quantifications of this potential burden. Former conceptual models and approaches for quantifying such impacts are available, though they are often high-level and difficult to utilize in practice. We therefore expand on this earlier work to incorporate heterogeneity in antimicrobial usage, AMR, and causative organisms, providing a detailed decision-tree-Markov-hybrid conceptual model to estimate the burden of AMR on surgery patients. We collate available data sources in England and describe how routinely collected data could be used to parameterise such a model, providing a useful repository of data systems for future health economic evaluations. The wealth of national-level data available for England provides a case study in describing how current surveillance and administrative data capture systems could be used in the estimation of transition probability and cost parameters. However, it is recommended that such data are utilized in combination with expert opinion (for scope and scenario definitions) to robustly estimate both the primary and secondary effects of AMR over time. Though we focus on England, this discussion is useful in other settings with established and/or developing infectious diseases surveillance systems that feed into AMR National Action Plans.
Identifiants
pubmed: 36033764
doi: 10.3389/fpubh.2022.803943
pmc: PMC9413182
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
803943Subventions
Organisme : Medical Research Council
ID : MR/P014658/1
Pays : United Kingdom
Informations de copyright
Copyright © 2022 Naylor, Evans, Pouwels, Troughton, Lamagni, Muller-Pebody, Knight, Atun and Robotham.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
PLoS One. 2020 Jan 10;15(1):e0227139
pubmed: 31923281
J Hosp Infect. 2013 Jun;84(2):106-19
pubmed: 23648216
Eur J Epidemiol. 2019 Jan;34(1):91-99
pubmed: 30219957
PLoS One. 2019 Sep 10;14(9):e0221944
pubmed: 31504046
BMJ Open. 2018 Feb 28;8(2):e020738
pubmed: 29490968
J Biomed Inform. 2013 Oct;46(5):830-6
pubmed: 23820016
Clin Microbiol Infect. 2018 Feb;24(2):105-109
pubmed: 28750921
Eur J Health Econ. 2013 Jun;14(3):367-72
pubmed: 23526140
J Clin Epidemiol. 2016 Nov;79:70-75
pubmed: 27237061
Lancet Infect Dis. 2019 Jan;19(1):56-66
pubmed: 30409683
J Pediatric Infect Dis Soc. 2015 Dec;4(4):305-12
pubmed: 26582869
Biom J. 2012 Sep;54(5):600-16
pubmed: 22847862
Lancet Public Health. 2021 Jan;6(1):e30-e38
pubmed: 33308423
Health Technol Assess. 2016 Jul;20(54):1-144
pubmed: 27468732
J Hosp Infect. 2018 Dec;100(4):378-385
pubmed: 29906490
Wellcome Open Res. 2019 Sep 24;4:140
pubmed: 32656364
J Am Med Inform Assoc. 2007 Jan-Feb;14(1):1-9
pubmed: 17077452
JAMA. 2016 Sep 13;316(10):1093-103
pubmed: 27623463
Bone Joint Res. 2015 Nov;4(11):181-9
pubmed: 26585304
BMJ Open. 2020 Jul 20;10(7):e036919
pubmed: 32690746
BMC Musculoskelet Disord. 2017 May 10;18(1):183
pubmed: 28486957
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
Clin Orthop Relat Res. 2015 May;473(5):1815-27
pubmed: 25267271
J Arthroplasty. 2018 May;33(5):1359-1367
pubmed: 29276115
Trials. 2020 May 12;21(1):398
pubmed: 32398093
Clin Infect Dis. 2020 Dec 3;71(9):e415-e420
pubmed: 32047916
Br J Surg. 2017 Jan;104(2):e134-e144
pubmed: 28093728
Lancet Infect Dis. 2015 Dec;15(12):1429-37
pubmed: 26482597
Pharmacoeconomics. 2015 Jan;33(1):31-48
pubmed: 25169062
J Innov Health Inform. 2016 Jan 19;22(4):426-32
pubmed: 26855276
World J Emerg Surg. 2019 Nov 21;14:50
pubmed: 31832084
Acta Orthop. 2014 Jun;85(3):244-9
pubmed: 24786908